PAD is kind of the silent disease that is many times found by accident and the patent received here is for a blood test to predict the likeliness of developing the disorder in the leg or ankle area. When you look at risk it’s all of us over 50 and a few other factors added in. A few months ago I had a chance to chat with Dr. Peter F. Lawrence, Director of the UCLA Gonda Vascular Center at UCLA on some of the new and innovative treatments they are performing for PAD with also providing a one stop shop for patients.
The UCLA Gonda Vascular Center Treats PAD (Peripheral Arterial Disease)-Interview with Dr. Peter Lawrence Chief of Vascular Surgery
From the website:
“In collaboration with researchers at Stanford University, Vermillion is developing a novel blood test to stratify an individual’s risk of developing PAD, a serious disease estimated to affect up to 12 million Americans.
VASCLIR® is a blood test that has been evaluated in four studies comprising almost 1,000 patients. It simultaneously evaluates various biomarkers for PAD and creates an index score. Vermillion studies have shown that patients with a high index score are seven times more likely to have PAD than patients with a low index score.”
There’s also the possibility of stem cell treatment with wound care, which is still considered investigational and not yet FDA approved yet, and the link below explains how it works.
Vermillion is also very active in women’s health with biomarkers for ovarian cancer and as mentioned works very close with Stanford University and the patent adds to their existing intellectual properties. BD
AUSTIN, Texas, May 17, 2011 /PRNewswire via COMTEX/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Panel of Biomarkers for Peripheral Artery Disease" to the company. The patent covers biomarker panels for the diagnosis of Peripheral Artery Disease. The data supporting the patent were published in an article titled, "A biomarker panel for peripheral arterial disease," in Vasc Med. 2008 Aug; 13(3):217-24. This work was done in coordination with Dr. John Cooke at Stanford University. Dr. Cooke is Professor and Associate Director of the Stanford Cardiovascular Institute at Stanford University School of Medicine.
"The notice of allowance for this PAD biomarker patent expands our intellectual property portfolio and adds to our first mover advantage. This is an asset the company believes could have significant commercial opportunity as we continue to develop and commercialize our VASCLIR(TM) test for PAD," said Gail S. Page, CEO of Vermillion.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found on the Web at www.vermillion.com.